Pediatric Tumor Board Series

The Pediatric Special Interest Track is pleased to present the next broadcast of the Pediatric Tumor Board Series. The broadcast entitled Posterior fossa ependymoma: Current upfront and relapse management strategies in the molecular era will occur live on May 24, 2022, 12:30-2:00 pm EDT.

Learning objectives:
- Review the relative therapeutic role and importance of surgery, radiation, and chemotherapy for primary and recurrent posterior fossa ependymoma
- Understand the biological and clinical significance of molecular sub-types and copy number alterations in posterior fossa ependymoma

Click here to register.

Reminder: Annual Meeting Abstract Deadline Approaching

Annual Meeting Abstract Deadline - June 1, 2022. This deadline will not be extended. For information on the submission categories and requirements, please click here. To submit an abstract, please click here.

From The Journals

From Neuro-Oncology
PI3K/AKT/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications
IDH-mutant diffuse gliomas are heterogeneous, and improved methods for optimal patient therapeutic stratification are needed. PI3K/AKT/mTOR signaling activity can drive disease progression and potential therapeutic inhibitors of the pathway are available. Yet, the prevalence of PI3K/AKT/mTOR signaling pathway activity in IDH-mutant glioma is unclear and few robust strategies to assess activity in clinical samples exist. Click here to read the full article.
Educational Programming

PI3K/AKT/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications
Dr. Evan Noch interviews Dr. Joanna Phillips about her and her team manuscript entitled: "PI3K/AKT/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications", published online in Neuro-Oncology in March 2022. Listen to the podcast.

Upcoming Webinar

The Society for Neuro-Oncology's Molecular Pathology Special Interest Track is pleased to announce the quarterly event for the SNO Pathology FAST (First Author Series Talk) webinar series. The webinar entitled Spatial Immunogenomic Heterogeneity of Malignant Brain Tumors will occur live on Monday May 16, 2022, at 1:00pm - 2:00pm EDT. Click here to register.

Member Submitted Clinical Question

I have a 41-year-old woman with a history of medulloblastoma that was successfully treated when she was a child. As you can imagine, she has several chronic health issues as a result of the treatment (needs walker to walk, is deaf, hard to control DM, neuropathy, cannot live fully independently, etc). Patient was wondering if anyone has a survivorship clinic for someone like her, or if not, does anyone have anticipatory protocols that they use for health maintenance in a long-term, now-adult medulloblastoma survivor. I looked through NCCN guidelines and did not find anything specific like this; more just piecemeal things about various individual treatment sequelae. Any help appreciated. Thanks!

To reply please email ledenise@med.umich.edu

Denise Leung, MD, MSc
Fellowship Program Director, Neuro-Oncology
Clinical Assistant Professor, Neurology
University of Michigan, Ann Arbor

SNO Career Center

This Week's Featured Listing
The Saint Luke’s Marion Bloch Neuroscience Institute (SLMBNI) is seeking a candidate for the position of the Neuro-Oncologist. The candidate should be board certified in neurology or medical oncology with fellowship training in neuro-oncology and experience in clinical research. Director of Neuro-oncology is available for candidates with at least five years of experience and demonstrated success in programmatic development. Click here to apply or see other postings!
Upcoming SNO and SNO Affiliated Events

The 20th International Symposium of Pediatric Neuro-Oncology (ISPNO 2022)
June 12-15, 2022, in Hamburg
Register Here

2nd Annual Conference on Clinical Trials and Brain Metastases
August 12-13, 2022 in Toronto, Canada
To view the program and to register click here.

Connect With SNO on Social Media

Are you following us on our socials? We're constantly sharing the latest news and events related to the neuro-oncology field. Check us out by clicking the links below.

SNO Digest Co-Editors
- Iyad Alnahhas, MD, MSc
- Wenya Linda Bi, MD, PhD
- L. Nicolas Gonzalez Castro, MD, PhD

SNO Team Admin Support
- Shelley Pressley - Director of Administration
- Gabrielle Griffin - Marketing and Communications Specialist

SNO Digest is written and distributed by the Society for Neuro-Oncology. All content, including images, may not be reproduced unless permission is granted from SNO. If you would like to contribute to upcoming issues of the SNO Digest or if you have questions, please contact us at snodigest@soc-neuro-onc.org.

See you in Tampa Bay!

27th Annual Meeting of the Society for Neuro-Oncology, November 16-20, 2022